FDA Investigator John A Podsadowski

John A Podsadowski has conducted inspections on 33 sites in 3 countries as of 27 Oct 2004. See below for a list of the FDA enforcement documents resulting from those inspections.

Investigator Details

Number of Inspected Sites:
33
Last Inspection Date:
27 Oct 2004
Investigator Role:
FDA Investigator
Redica ID:
100004801
Countries of Inspections:
United States of America, United Kingdom of Great Britain and Northern Ireland, Finland
FDA Investigators that have inspected at least one site in common with John A Podsadowski:
Alice S Tsao, Anastasia M Shields, Ann B Okon, Ann L Demarco, Benton M Ketron, Bijoy Panicker, Brian J Ryan, Bruce G Cooper, Bruce H Mccullough, Candace Y Gomez Broughton, Charanjeet Jassal, Charisse K Green, Daniel L Aisen, David M Mcnew, David R Delucia, Demitria J Xiradakis, Dennis E Guilfoyle, PhD, Don H Bark, PhD, Donald G Gordon, Dr. Barbara D Paul, PhD, Dr. Robert C Horan, MD, Erika E Englund, PhD, Erin L Nagel, Felix Maldonado, Gary T Greco, George J Flynn, Harry J Brewer, Helen B Ricalde, James A Liubicich, James D Bridges, Jazmine N Brown, Joanne M Schlossin, Joel R Merriman, Johnna L Bleem, Jose Ohernandez Guzman, Joseph A Famiglietti, Joseph J Vannelli, Judy Keihl, Karen L Kosar, Kathryn A Nagy, Kenneth G Klobus, Kenneth H Williams, Kevin A Gonzalez, Kim M Downing, Kimberley A Ricketts, Lauren E Blaser, Lawrence W Farina, Linda M Sacco, Marcellinus D Dordunoo, Margaret E Sarles, Mark E Parmon, Matthew A Spataro, Matthew D Schnittker, Melba Trivera Clavell, Michael A Charles, Michael Levin, Michael W Burd, Mindy M Chou, Mra V Millarw, Nancy A Saxenian Emmons, Nicholas C Mendiola, Niketa Patel, Parul M Patel, Patricia A Clark, Patricia F Hughes, PhD, Patrick C Klotzbuecher, Paul E Stein, Paul L Bellamy, Paul Mouris, Peter Abel, Rajiv R Srivastava, Rashmi Rawat, PhD, Richard E Needham, Richard K Glabach, Robert C Coleman, Robert C Steyert, Russ E Davis, Samuel T Walker, Shari L Kahn, Simone E Pitts, Sony Mathews, Steven J Libal, Syeda N Mahazabin, Tiffani D Wilson, Uduak M Inokon, Wendy G Tan, PhD, William J Leonard, William M Rennells, William P Chilton, Xiaokuang Lai, PhD, Yuyan Liang, Yvesna C Blaise

John A Podsadowski's Documents

Publish Date Document Type Title
August, 2002 EIR Arkema Inc. - EIR, 2002-08-16
July, 2000 FDA 483 Wyeth Pharmaceuticals Inc., a subsidiary of Pfizer, Inc. - Form 483, 2000-07-21
February, 2000 FDA 483 Fresenius Kabi USA, LLC - Form 483, 2000-02-25
September, 2003 EIR Ortho Clinical Diagnostics - EIR, 2003-09-17
July, 2000 FDA 483 Response Wyeth Pharmaceuticals Inc., a subsidiary of Pfizer, Inc. - Form 483R, 2000-07-25
August, 2004 EIR Fresenius Kabi USA, LLC - EIR, 2004-08-09
December, 2000 FDA 483 Bristol-Myers Squibb Co., Inc. - Form 483, 2000-12-15
August, 2003 EIR Unither Manufacturing LLC - EIR, 2003-08-29
May, 2000 FDA 483 Response Fresenius Kabi USA, LLC - Form 483R, 2000-06-16
February, 2001 FDA 483 Bristol-Myers Squibb Co., Inc. - Form 483, 2001-02-01
July, 2002 EIR Mentholatum Company, The - EIR, 2002-07-26
May, 2003 FDA 483 Fresenius Kabi USA, LLC - Form 483, 2003-05-30
May, 2003 FDA 483 Response Fresenius Kabi USA, LLC - Form 483R, 2003-06-19
May, 2001 FDA 483 Response Fresenius Kabi USA, LLC - Form 483R, 2001-06-18
February, 2002 EIR Contract Pharmaceuticals Limited Niagara - EIR, 2002-02-13
February, 2000 FDA 483 Response Fresenius Kabi USA, LLC - Form 483R, 2000-03-24
February, 2002 FDA 483 Contract Pharmaceuticals Limited Niagara - Form 483, 2002-02-13
May, 2000 FDA 483 Fresenius Kabi USA, LLC - Form 483, 2000-05-15
May, 2004 EIR Astellas Pharma Manufacturing, Inc. - EIR, 2004-05-06
August, 2001 EIR Bristol-myers Squibb Pharma Company - EIR, 2001-08-24
August, 2001 FDA 483 Response Bristol-myers Squibb Pharma Company - Form 483R, 2001-09-06
February, 2000 EIR Fresenius Kabi USA, LLC - EIR, 2000-02-25
February, 2001 EIR Bristol-Myers Squibb Co., Inc. - EIR, 2001-02-01
May, 2001 FDA 483 Fresenius Kabi USA, LLC - Form 483, 2001-05-25
January, 2003 EIR Contract Pharmaceuticals Limited Niagara - EIR, 2003-01-15
August, 2001 FDA 483 Bristol-myers Squibb Pharma Company - Form 483, 2001-08-24

Experience Redica Systems’ NEW investigator profiles and dashboards

Redica Systems customers get access to over 1,400 FDA Investigator profiles, containing powerful analysis like:

  • Total inspections conducted
  • 483 rate
  • OAI rate
  • Warning Letter rate
  • Inspections by Industry, Scope, and Inspection Reason
  • And much more

Investigator Profiles are not sold as on-demand documents. If you’d like to see one, fill out the form below to connect with our Sales Team and get it in your inbox as little as 24 hours.

FDA Investigator Profile Icon

Talk to sales to access our investigator profiles

Loading...

Investigator Profiles Are Just the Tip of the Iceberg

Becoming a Redica Systems customer not only provides you with unlimited access to profiles similar to the one above for every current and former FDA Investigator, but also grants you access to:

Inspection Intelligence

  • Pre-Approval Inspection (PAI) trends
  • The ability to filter nearly any FDA enforcement action by GxP labels like GMP, GCP, etc.
  • Latest 483s: see what the trends are across all FDA Investigators
  • CFR Heatmap: Citations aggregated by Subpart by Year

Vendor Intelligence

  • Full inspection histories for your vendors down to the specific site level
  • All of the functionality mentioned above but isolated to just your vendors

Regulatory Intelligence

  • Zero in on the trends for a specific agency/regulator (ex. FDA, MHRA, EMA, Health Canada)
  • All the latest "Signals" from agencies around the world, segmented by Country, Type (ex. Guidance, Decree...), Category (ex. Rules/Regulations/Guidance, News, Reports...), Theme (ex. Cell and Gene Therapy, AI...), and more